Naturally Occurring Cardiac Peptides
New Mechanism for the Treatment of Cancer
Cytostatic not Cytotoxic
Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer. Kalos is aggressively targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation). Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.
Anti Cancer Bio-technology
Kalos has successfully leveraged the natural antiproliferative activity of the Atrial Natriuretic Peptide (ANP) family of peptides in our patented Kalos Motif (s) demonstrating never before seen anti cancer growth properties. Kalos has efficaciously identified the motif in this family of peptides that is responsible for controlling cell growth (the anti-cell proliferation motif, or ACM), and is developing a new class of anti-proliferative drugs based on this motif.
Kalos Therapeutics is developing peptides with broad spectrum anti tumor activity and a NON-TOXIC side effect profile